The University of Lausanne is offering this technology for licensing or for collaboration.

The technology describes methods to identify highly efficient epithelial sodium transporters inhibitors.

Development Phase :
Proof of principle

Patent Status :
A provisional patent application has been filed on September 2000.

Patent Attorney : Mintz & Levin, Boston, USA

Novelty and Benefits :

As the target site for the effectors is intracellular, a lower drug concentration will be needed, compared to current renal treatments of hypertension.

Additional information is available upon request

Contact :
Marjory Hunt, PhD
tel: +41-21-314-4958
fax: +41-21-314-4957

Pactt

Office of Technology Transfer
University of Lausanne and University Hospitals
21, Rue du Bugnon
Ch-1005 Lausanne
e-mail: marjory.hunt@hospvd.ch

Sodium Channel Inhibitors

(Ref. Number IDF 8.00)

The Technology :
The technology pertains to methods for identifying highly efficient inhibitors of the epithelial sodium channel ENaC. Hyperactivity of ENaC causes sodium retention, expansion of extracellular fluid and hypertension.

Specific sequences have been identified on each subunit of the ENaC sodium channel. Reversible binding to these sequences inhibits sodium channel activity. The protein domains corresponding to these sequences are intracellular.

Applications :
These methods are of use for the treatment of pathological conditions including hypertension, renal insufficiency, any electrolyte imbalance, cystic fibrosis, Liddle s syndrome as well as any other disease and/or syndrome known to be caused by irregular or inappropriate activity of ENaC.